Bird Flu: What You Need to Know Now

You may have seen recent news reports about the bird flu virus and the possibility that this virus could affect humans and our food supply, notably with milk from cows. Government health officials say there is no reason for concern, and experts at Mount Sinai agree.

“People should be aware, monitor the situation, and follow the guidelines of health authorities,” says Bernard Camins, MD, MSc, Professor of Medicine (Infectious Diseases) at the Icahn School of Medicine at Mount Sinai and the Medical Director for Infection Prevention for the Mount Sinai Health System.

The issue arose when a bird flu virus was detected in dairy cows in eight states. The concern is that this virus could pass to consumers who drink milk from infected cows.

The Food and Drug Administration (FDA) says tests have shown the commercial milk supply is safe. The FDA says the pasteurization process heats milk up to a high enough temperature to kill harmful germs, and milk from sick cows is diverted and not sold. Even if virus is detected in raw milk, pasteurization eliminates pathogens to a level that does not pose a risk to consumer health, according to Dr. Camins and the FDA.

Although bird flu viruses do not normally infect humans, sporadic human infections have occurred, according to the U.S. Centers for Disease Control and Prevention (CDC).

Click here for the latest updates from the CDC

On Monday, April 1, the CDC announced that one person in Texas had tested positive for a strain of the bird flu virus referred to as H5N1. The person was exposed to dairy cattle that were presumed to be infected.

The patient reported eye redness and is recovering. The patient was told to isolate and was treated with an antiviral drug for flu, according to the CDC. This is the second person reported to have tested positive for bird flu in the United States. A previous human case occurred in 2022 in Colorado.

The CDC says the risk these viruses pose to the public remains low. It recommends that people should avoid being near sick or dead animals. Also, people should not prepare or eat uncooked or undercooked food or related uncooked food products, such as unpasteurized (raw) milk or cheeses, according to the CDC. Dr. Camins says people should normally avoid eating avoid raw milk and raw cheeses because of the potential for contracting other infections and not just bird flu.

According to the New York State Department of Health, bird flu is caused by a group of viruses that occur naturally in wild birds. Animal health officials are watching closely for bird flu in poultry and wild birds in the United States. Early detection of the virus in poultry and wild birds is important to prevent the spread of bird flu, especially into commercial poultry flocks, the Department says.

Annual Symposium of the Biomedical Engineering and Imaging Institute Focuses on Precision Medicine and the Future of Digital Medicine

The 12th annual symposium of the Biomedical Engineering and Imaging Institute (BMEII) at the Icahn School of Medicine at Mount Sinai focused on precision medicine and the future of digital health.

The event featured renowned academic and industry representatives from around the world who participated in panel discussions about the precision medicine imperative and the quest to extend the “health span”—defined as the number of years people live a heathy life free of disease—in a multidisciplinary manner with a focus on medical imaging and engineering.

The innovation station and poster session provided hands-on demonstrations of current research.

More than 325 people, including researchers, physicians, industry leaders, medical students, and high school students, attended the event at the New York Academy of Medicine. The event was held Wednesday and Thursday, March 20-21.

The symposium began with welcome remarks from BMEII’s Director Zahi A. Fayad, PhD, who emphasized the need to back up recent developments in screening, longevity, and pharmaceuticals with evidence and data. He shared this vision during the event, ensuring attendees walked away with a better and more holistic understanding of the current and future state of precision medicine.

A major highlight of the symposium was the panel discussion about the future of digital medicine. With five industry and academic leaders, this discussion addressed many of the challenges health care is facing as consumer health technologies grow rapidly and move into clinical areas. These challenges center on user compliance and data privacy.

“I think the biggest problem is also trying to get the stakeholders around the same table and developing some consensus as to how they can share, if not the proprietary information, but how can they kind of use all of that [data] towards the good of humankind,” said Jagmeet P. Singh, MD, ScM, DPhil, Professor of Medicine at Harvard Medical School. He works closely with patients within the cardiology department who have received implantable cardiac devices and has first-hand experience with the long-term challenges that come with working with multiple manufacturers.

“So, now you have third-party vendors—in fact, over the course of the last year, there are almost 120 different remote monitoring companies that have come up—that are trying to standardize the data from these implantable devices that can be used uniformly by all health care givers,” he added.

Brendan Carr, MD, MA, MS

The symposium also included sessions for high school, undergraduate, and graduate students to build their interest in scientific research. A professional development panel, hosted by PhD candidates at Icahn Mount Sinai, allowed leaders in the field to share their personal experiences, challenges, and successes with the students. The innovation station and poster session provided hands-on demonstrations of current research in the medical imaging space by BMEII members and scientists from other institutes.

Health care is bound to change in dramatic ways in the future, and the symposium addressed the research and innovation that is shaping these changes.

Brendan Carr, MD, MA, MS, Chief Executive Officer of the Mount Sinai Health System, summarized the importance of the research BMEII is doing: “The clinical delivery system doesn’t exist without the pioneering research portfolio, and the pioneering research portfolio exists because it’s so unbelievably compelling to save lives and improve people’s health outcomes. That synergy is special—it’s a big piece of what this conference is about.”

PhD Candidate Bryce Rowan Shares How the Resources at Mount Sinai Are Instrumental in Helping Him Reach His Goals

Bryce Rowan

Bryce Rowan is a third-year doctoral candidate in the Genetics and Genomics multidisciplinary training area (MTA) of the PhD in Biomedical Sciences program. In this Q & A, he discusses why he chose to study at the Icahn School of Medicine at Mount Sinai.

What attracted you to this area of study?

I am interested in translational work and being able to apply my findings to human studies in attempts to aid in improving the equitable study and treatment of neuropsychiatric diseases.

Why continue your education with a PhD in Biomedical Sciences?

I need a PhD to understand research strategies and manage multiple projects. This will enable me to become a Principal Investigator one day.

 Why did you choose to study at Icahn Mount Sinai?

The resources at Icahn Mount Sinai drew me to the program. We have functional genomics datasets and biobank datasets with plenty of computational storage and computing power to properly analyze these datasets.

What activities outside the classroom have contributed to your success?

Finding community, specifically friends outside of the graduate program, helps provide balance and is necessary for work-life balance. Volunteering my time by mentoring and working to produce an environment that better accounts for mental health and wellness through the Trainee Health and Wellness program also provides me with a way to give back to the graduate school community. Having a life outside of work is imperative, and giving back is crucial to success.

What are your plans after you complete your PhD?

I’m seeking a job as a postdoctoral fellow where I can gain independent funding, while also having more independent projects. My training in the PhD program makes this a good next step for my career.

Annual Gala Celebrates Advances in Prostate Cancer Research and Treatment at Mount Sinai

Frorm left: James Tisch, Co-Chairman of the Boards of Trustees of the Mount Sinai Health System, Dennis Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, and Ash Tewari, MBBS, MCh.

The Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai hosted its annual Prostate Cancer Research Gala and exceeded its goal of raising more than $1 million for the Center of Excellence for Prostate Cancer within the Department of Urology. Its mission is to eliminate prostate cancer through programs that support innovative research, patient care, prevention, and education for students, trainees, professionals, and the public.

“We are fortunate that at Mount Sinai the best minds across specialties like immunology, pathology, medical oncology, radiology, and others collaborate with the common goal of making prostate cancer insignificant while improving the quality of life for our patients,” said Ash Tewari, MBBS, MCh, Chair of the Department of Urology at the Mount Sinai Health System and the Kyung Hyun Kim, MD Professor of Urology at Icahn Mount Sinai, who spearheaded the gala and directs the Center of Excellence.

Goutam Chakraborty, PhD, left, and Dr. Charney

More than 200 people attended the event, which was held Wednesday, April 10, at the Rainbow Room in Rockefeller Center. Actor and singer Peter Gallagher served as the emcee for the evening.

At the event, the second annual Steven Southwick, MD Memorial Award was presented to Goutam Chakraborty, PhD, Assistant Professor, Urology, and Oncological Sciences and a member of The Tisch Cancer Institute at Mount Sinai. Named after renowned researcher and scientist Steven M. Southwick—a leading expert in psychological trauma and human resilience, who passed away in 2022 after a lengthy battle with prostate cancer—this award recognizes outstanding achievements in prostate cancer research.

Dr. Chakraborty was honored for his focus on lethal metastatic prostate cancer, which has no available treatments. He and his team made the groundbreaking discovery that the BRCA2 gene—most commonly known for its link to breast cancer—also has a connection to prostate cancer. Dr. Chakraborty is now looking at how mutations of genes like BRCA2 change cells from benign to metastatic disease, potentially leading to important new therapies.

“Research is like climbing a mountain, like climbing Everest, but we have not reached the top of Everest yet,” said Dr. Chakraborty in a video shown at the event. “Every day is a different challenge.”

Dr. Tewari, left, and John A. Levin

The gala also honored John A. Levin, who was recognized for his extraordinary commitment to the Prostate Cancer Program and longtime leadership on the Mount Sinai Board of Trustees. Dr. Tewari praised Mr. Levin’s unwavering support of the Mount Sinai Health System’s efforts to redefine cancer care, including his involvement with the International Prostate Cancer and Urology Symposium held at Mount Sinai, which draws the world’s top experts together to explore the latest advancements and challenges in urological cancer.

“His philanthropy has made an immense impact, not just on our prostate cancer program, but on a global understanding of prostate cancer, and to Mount Sinai itself, guiding and supporting research in different subspecialties,” said Dr. Tewari in a video.

In accepting the award, Mr. Levin noted that he’s proud to be part of Mount Sinai’s extraordinary service to New York City and beyond.

“We treat an enormous number of people. It is also an education arm and a research institution which creates new drugs, creates new devices,” he said in a video. “It’s really being part of a community and I want to help that community in whatever limited capacity I can.”

Team at Mount Sinai Fuster Heart Hospital Performs Milestone Procedure With Newly FDA-Approved Therapy

Members of the team at Mount Sinai Fuster Heart Hospital, from left: Lucy Safi, DO, FACC, FASE, FSCAI, Sahil Khera, MD, MPH, Gilbert H.L. Tang, MD, MBA, MSc, Stamatios Lerakis, MD, PhD, David H. Adams, MD, Samin K. Sharma, MD, Annapoorna S. Kini, MD, Parasuram Krishnamoorthy, MD, and Jin Kang, MD.

A team at Mount Sinai Fuster Heart Hospital has achieved a groundbreaking milestone, with Gilbert H.L. Tang, MD, MBA, MSc, Surgical Director of the Structural Heart Program, and Annapoorna S. Kini, MD, Director of the Cardiac Catheterization Laboratory, and team performing one of the first tricuspid transcatheter edge-to-edge repair (T-TEER) procedures in the United States with a newly Food and Drug Administration-approved therapy.

This new therapy revolutionizes the treatment of tricuspid regurgitation, a condition in which the valve between the two right heart chambers (right ventricle and right atrium) doesn’t close properly, allowing blood to flow backward into the right atrium of the heart. This minimally invasive therapy repairs the tricuspid valve without the need for open-heart surgery.

“Having a first transcatheter repair device approved for patients with tricuspid regurgitation is a game changer,” says Dr. Tang. “We have already performed several procedures since FDA approval and their recoveries have truly been remarkable.”

“The tricuspid TEER therapy will be a life saver for many patients who can’t undergo open heart surgery,” says Samin K. Sharma, MD, Director of Interventional Cardiology for Mount Sinai Health System.

David H. Adams, MD, Cardiac Surgeon-in-Chief of the Mount Sinai Health System, was one of the two national co-principal investigators who ran the clinical trial that secured FDA approval for tricuspid TEER. Trial results showed its safety, and found that it reduced the severity of tricuspid regurgitation and enhanced quality of life for patients.

“As we celebrate this pivotal moment, we’re filled with gratitude for the dedication of our team at Mount Sinai Fuster Heart Hospital,” says Dr. Sharma. “Together, we’re shaping a future where innovative treatments bring hope and healing to those in need.”

How the Intersection of Biology and Technology Inspired Angie Ramirez to Study Biomedical Data Science at Mount Sinai

Angie V Ramirez Jimenez

Angie V Ramirez Jimenez is a second-year student in the Master of Science in Biomedical Data Science program. In this Q&A, she discusses why she chose the Icahn School of Medicine at Mount Sinai.

Why did you decide to study at Icahn Mount Sinai?

After completing my undergraduate degree, I came to Mount Sinai to work as a research associate in the lab of Michelle E. Ehrlich, MD, and Samuel Gandy, MD, PhD, in the Neurology Department. There I had the opportunity to work on various projects that investigate the mechanisms of neurodegenerative disorders including Alzheimer’s disease, dystonia, and Huntington’s disease, and learn about all the research opportunities that were available at Mount Sinai. The chance to learn from professors at the forefront of biomedical research made it the ideal place for me to expand my knowledge and skills.

What attracted you to study Biomedical Data Science? What about it inspires you?

My journey into Biomedical Data Science stemmed from a fascination with the intersection of biology and technology. The realization of the potential of programming to revolutionize scientific research sparked my interest in this field. I was inspired by the ability of data science to unlock insights from various biological datasets, leading to a deeper understanding of complex biological systems. The prospect of using data to drive advancements in precision medicine and ultimately improve patient outcomes motivated me to pursue a career in Biomedical Data Science.

What were some of your achievements as a master’s student?

During my time as a master’s student, I trained and worked in the Bioinformatics for Next Generation Sequencing (BiNGS) core at The Tish Cancer Institute at Mount Sinai. At the core, I was able to contribute to various projects, in addition to my own capstone project, which included assessing the effectiveness of a novel keratinocyte differentiation protocol on induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs), as well as investigating the impact of different extracellular matrix (ECM) environments on cancer cell dormancy. For my capstone project, I analyzed RNA-seq, ATAC-seq, and CUT&RUN data to dissect the epigenetic and transcriptional landscapes of hepatocellular carcinoma models.

What activities outside the classroom have contributed to your success?

I believe that my involvement in research projects outside the classroom have been pivotal to my success. As an undergrad, I went on a research trip to Costa Rica to investigate the resilience of microbial communities in Costa Rica’s rainforests post-hurricane. This was the first time I was part of real-world scientific research, and thanks to that, I saw a side of research I had not seen in the classroom—large-scale data analysis and how powerful it can be in understanding complex biological interactions.

This experience helped me realize this was something I wanted to pursue and once I started working in the Ehrlich/Gandy lab I was able to pursue my interest in bioinformatics and work alongside great postdocs who mentored me on how to do various types of analysis.

I’ve also worked at Liberty Science Center in Jersey City, New Jersey, where I taught kids how to do different lab experiences. I think working with the kids really taught me how not to make assumptions about how much people may know about a topic, which really helps me when trying to teach others. I also learned that everyone has the power to make an impact on others even when we may not realize it.

I think that just being open minded and not closing yourself off to opportunities, even when they seem very daunting or even insignificant, when they come is really what helps you learn and grow. Sometimes opportunities arise from the most unexpected places, but you will never find them if you don’t put yourself out there.

What are your plans after you have completed your degree?

I plan to continue my journey in the field of Biomedical Data Science. My goal is to help make a positive impact in the biomedical field, potentially preventing others from experiencing the loss of loved ones to diseases like cancer. In the distant future, I also hope to open a bike shop that can also serve as a sort of community center where people can connect with others and learn about bikes.

Pin It on Pinterest